Long-term effects of rivastigmine in moderately severe Alzheimer's disease: Does early initiation of therapy offer sustained benefits?

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 26, Issue 4, 2002, Pages 705-712

  Doraiswamy, P Murali ^a   Krishnan, K Ranga Rama ^b   Anand, Ravi ^c   Sohn, Hyesung ^c   Danyluk, Jacquiline ^c   Hartman, Richard D ^c   Veach, Jeffrey ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Alzheimer's disease; Cholinesterase inhibitor; Efficacy; Rivastigmine

Indexed keywords

CARBAMIC ACID DERIVATIVE; RIVASTIGMINE; DONEPEZIL; GALANTAMINE; TACRINE;

AGED; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; TIME; AGITATION; ANOREXIA; COGNITION; CONFUSION; DEMENTIA; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; MAJOR CLINICAL STUDY; NAUSEA; RATING SCALE; VOMITING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; CARBAMATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PHENYLCARBAMATES; TIME; COMPARATIVE STUDY; HUMAN; SUPPORT, NON-U.S. GOV'T;

EID: 0036016290     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(01)00326-8     Document Type: Article

References (23)

1. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
2. Cholinergic drugs in Alzheimer's disease
3. Brain Selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease
4. The effects of tacrine in patients with mild versus moderate stage Alzheimer's disease
5. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease
6. An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease
7. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
8. The stages of Alzheimer's Disease: A reappraisal
9. Defining meaningful change in Alzheimer's disease trials: The donepezil experience
10. The Global Deterioration Scale for assessment of primary degenerative dementia
11. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
12. A new rating scale for Alzheimer's disease
13. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
14. A longitudinal study of Alzheimer's disease: Measurement, rate, and predictors of cognitive deterioration
15. A 5-month, randomized, placebo-controlled trial of galantamine in AD